Serum positive group
| Case | Age/sex | Site | HCG serum/ CSF (mIU/ml) | HCG-β serum/ CSF (ng/ml) | Initial treatment | Recurrence | Treatment at recurrence | Latest follow up |
|---|---|---|---|---|---|---|---|---|
| 1 | 13/M | P | 40/88 | 0.41/1.5 | R | — | — | 12 y/alive |
| 2 | 12/M | BG | 130/90 | 3.5/6.3 | R | — | — | 15 y/alive |
| 3 | 9/M | S | 78/96 | 0.57/1.34 | Chem | — | — | 7 y/alive |
| 4 | 13/M | P | -/- | 0.3/2.3 | Chem | 6 months; local | Cranial irradication | 2 y/alive |
| 5 | 16/M | P | 56/70 | 0.54/0.78 | R | 14 months; spinal | Spinal irradication | 4 y/died of tumour |
| 6 | 22/M | P | 6.9/22 | 0.47/1.1 | Chem | 5 y; local CSF HCG-β (+), normal serum HCG-β | Cranial irradication | 7 y/alive |
| 7 | 16/M | BG | 6.4/8.0 | 0.4/0.9 | Chem | 3 y; local | Cranial irradication | 7 y/alive |
BG=basal ganglia; P=pineal; S=suprasellar; R=radiotherapy (whole brain, 30 Gy; local 20 Gy); Chem=chemotherapy; HCG=human chorionic gonadotrophin; HCG-β=human chorionic gonadotrophin β-subunit; -/- =not tested.